[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382862":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":83,"collaborators":22,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":22,"enrollmentInfo":95,"targetDuration":22,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":51,"whyStopped":22,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"subjects SSc diagnosed","EXPERIMENTAL","Patient with systemic scleroderma according to the American College of Rheumatology (ACR) \u002F EULAR 2013 criteria",[13,14,15],"Biological: Blood samples","Other: Biopsy","Other: Bronchoalveolar samples",[17,23,27,31],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"BIOLOGICAL","Blood samples","62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation",[9],null,{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Biopsy","Skin biopsies only for volunteers among patients",[9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Bronchoalveolar samples","50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients",[9],{"type":6,"name":24,"description":32,"armGroupLabels":33,"otherNames":22},"Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients",[9],[35],{"name":36,"affiliation":5,"role":37},"Marie-Elise TRUCHETET, MD, PhD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","05.56.79.55.56","+33","marie-elise.truchetet@chu-bordeaux.fr",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Thomas BARNETCHE, PhD","05.57.82.04.93","thomas.barnetche@chu-bordeaux.fr",[49],{"facility":50,"status":51,"city":52,"state":22,"zip":22,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"CHU de Bordeaux - service de rhumatologie","RECRUITING","Bordeaux","France","FR",{"type":56,"coordinates":57},"Point",[58,59],-0.58046,44.84124,{"lat":59,"lon":58},[62,63,64,66,69,71,73,75,77,79,81],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},{"name":65,"role":37,"phone":22,"phoneExt":22,"email":22},"Marie-Elise TRUCHETET, MD",{"name":67,"role":68,"phone":22,"phoneExt":22,"email":22},"Joel CONSTANS, Prof","SUB_INVESTIGATOR",{"name":70,"role":68,"phone":22,"phoneExt":22,"email":22},"Julien SENESCHAL, Prof",{"name":72,"role":68,"phone":22,"phoneExt":22,"email":22},"Estibaliz LAZARO, Prof",{"name":74,"role":68,"phone":22,"phoneExt":22,"email":22},"Elodie BLANCHARD, MD",{"name":76,"role":68,"phone":22,"phoneExt":22,"email":22},"Francois PICARD, MD",{"name":78,"role":68,"phone":22,"phoneExt":22,"email":22},"Pierre DUFFAU, Prof",{"name":80,"role":68,"phone":22,"phoneExt":22,"email":22},"Pauline RIVIERE, MD",{"name":82,"role":68,"phone":22,"phoneExt":22,"email":22},"Fabrice BONNET, Prof",{"type":84,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100382862","cohort-of-patients-with-systemic-sclerosis-within-the-framework-of-the-reso-reference-centre-100382862",false,"NCT04265144","Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre","Cohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune Diseases","SCLERESO","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient with systemic scleroderma according to the ACR\u002FEULAR 2013 criteria, or with a \" very early systemic sclerosis \" defined by the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1\u002F160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity).\n* Person affiliated or benefiting from a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Patient under guardianship, curatorship or any other legal protection regime","ALL","18 Years",{"count":96,"type":97},500,"ESTIMATED","INTERVENTIONAL",[100],"NA","Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.",[103,104],"Scleroderma","Systemic Sclerosis",[106,107,108],"Cohort study","systemic sclerosis","prognosis","2025-09-03",{"date":111,"type":112},"2025-09-04","ACTUAL",{"date":114,"type":112},"2020-06-08",{"date":116,"type":97},"2034-06",{"name":5,"class":6},1]